References
Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor–based regimens. Presented at 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 26-28, 2015; Washington DC.
The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018;46(8):1212-1225.
. Drug-drug interaction profile of sofosbuvir/velpatasvir/voxilaprevir fixed dose combination [FRI-187]. J Hepatol. 2017;66(1):S492-S493.
Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J Clin Exp Hepatol. 2020;10(3):189-193.
. Transient elastography in clinical detection of liver cirrhosis: a systematic review and meta-analysis. Saudi J Gastroenterol. 2016;22(4):294-303.
. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729-738.
. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14(1):156-164.e3.
. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19-21, 2014; Washington DC.
. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals [abstract 82]. Presented at 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000;32(2):293-299.
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444.
. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124(1):97-104.
Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5(4):303-306.
Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. J Heart Lung Transplant. 2020;S1053-2498(20):31624-7.
. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39(4):620-627.
. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21(6):653-662.
. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018;33(12):2029-2036.
. Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;377(11):1105. doi:10.1056/NEJMc1709315.
. .